Floatz logo

Theprubicin

Melanoma

National Institutes of Health Clinical Center (CC)Small moleculePhase 1Dormant
C
37/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
65/ 100

Competitive context

329 Active assets in the Melanoma cohort.

Asset / SponsorPhaseRating
DACARBAZINE
Suzhou BlueHorse Therapeutics Co., Ltd.
Phase 3BB
Cyclophosphamide
Primmune Therapeutics, Inc.
Phase 4BB
Nivolumab
Bristol-Myers Squibb
Phase 4BB
Epirubicin
Primmune Therapeutics, Inc.
Phase 4BB
Pembrolizumab
Biocon Biologics UK PLC
Phase 4BB

View all 50 →

Same molecule, other indications

Theprubicin is also rated in:

hepatocellular carcinomaDormant
BB
Indicative ·
71 / 100
View asset →
Transarterial ChemoembolizationDormant
BB
Indicative ·
66 / 100
View asset →
Colon Cancer Liver MetastasisDormant
BB
Indicative ·
66 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →